Innate Pharma (IPHA) Liabilities and Shareholders Equity (2017 - 2025)

Innate Pharma (IPHA) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $118.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Liabilities and Shareholders Equity fell 37.04% year-over-year to $118.7 million, compared with a TTM value of $816.5 million through Dec 2024, down 23.29%, and an annual FY2024 reading of $120.2 million, down 36.57% over the prior year.
  • Liabilities and Shareholders Equity was $118.7 million for Q4 2024 at Innate Pharma, down from $188.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $366.5 million in Q4 2020 and bottomed at $118.7 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $236.6 million, with a median of $203.3 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity decreased 7.3% in 2023, then plummeted 37.04% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $366.5 million in 2020, then decreased by 16.51% to $306.0 million in 2021, then tumbled by 33.55% to $203.3 million in 2022, then fell by 7.3% to $188.5 million in 2023, then tumbled by 37.04% to $118.7 million in 2024.
  • Business Quant data shows Liabilities and Shareholders Equity for IPHA at $118.7 million in Q4 2024, $188.5 million in Q4 2023, and $203.3 million in Q4 2022.